Novavax, Inc.

NASDAQ:NVAX   3:59:59 PM EDT
237.54
+0.27 (+0.11%)
4:50:37 PM EDT: $234.65 -2.89 (-1.22%)
Products, Regulatory, Other Pre-Announcement

Novavax Initiates Phase 1/2 Trial Of Combination Vaccine For COVID-19 And Seasonal Influenza

Published: 09/08/2021 12:57 GMT
Novavax, Inc. (NVAX) - Novavax Initiates Phase 1/2 Clinical Trial of Combination Vaccine for Covid-19 and Seasonal Influenza.
Novavax Inc - First Participants Enrolled in Phase 1 Clinical Trial of Combination Nanoflu™/nvx-cov2373 Vaccine With Matrix-m™ Adjuvant.
Novavax Inc - Phase 1/2 Trial Will Be Conducted in Australia at Up to 12 Study Sites, With Results Expected During First Half of 2022.